Inflammatory Biomarkers from Blood Counts as Prognostic Tools in Metastatic Esophageal Cancer

Basit Öğe Kaydı
dc.contributor.authorUrun, Yonca Yilmaz
dc.contributor.authorBeypinar, Ismail
dc.date.accessioned2026-01-24T12:29:11Z
dc.date.available2026-01-24T12:29:11Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBackground: Globally, esophageal cancer ranks as the sixth leading cause of cancer-related mortality. This retrospective study from a single center in Turkey aimed to evaluate hematological inflammatory biomarkers in complete blood count (CBC) data and outcomes in 113 patients with advanced esophageal carcinomas. Material/Methods: We conducted a retrospective analysis of 113 patients with metastatic esophageal cancer composed of squamous (92), adenocarcinoma (18), and small cell (3) histology. We investigated neutrophil-to-lymphocyte ratio tory response index (SIRI), and aggregate index of systemic inflammation (AISI) in terms of prognosis. Results: The initial treatment for 25.7% of patients consisted of a carboplatin-paclitaxel combination. In response to the initial round of chemotherapy, 52.2% of patients showed improvement (15% complete, 37.2% partial), while 18.6% experienced disease progression. Neutropenia was observed as the most prevalent severe (grades 3-4) adverse reaction, affecting 19.8% of patients. Higher NLR, PLR, SII, NLPR, SIRI, and AISI values were associated with worse survival (P=0.016, P=0.008, P=0.011, P=0.028, P=0.014, P=0.001, respectively), whereas higher LMR was correlated with better survival (P=0.001). The NMR analysis showed no significant association (P=0.46). Multivariate analysis identified independent prognostic factors except histology, PLR, and NLPR. Conclusions: Research indicates that inflammatory indicators obtained from complete blood count analyses possess prognostic significance for individuals with metastatic esophageal cancer. These biomarkers demonstrate diverse capacities in forecasting the course of the disease. These simple and inexpensive markers need further confirmation to guide individualized treatment planning.
dc.identifier.doi10.12659/MSM.947202
dc.identifier.issn1643-3750
dc.identifier.pmid39923126
dc.identifier.scopus2-s2.0-85217803354
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.12659/MSM.947202
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5184
dc.identifier.volume31
dc.identifier.wosWOS:001422049800001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherInt Scientific Information, Inc
dc.relation.ispartofMedical Science Monitor
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectBlood Cell Count
dc.subjectEsophagus
dc.subjectInflammation
dc.subjectPrognosis
dc.titleInflammatory Biomarkers from Blood Counts as Prognostic Tools in Metastatic Esophageal Cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu